Compare FONR & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FONR | NSPR |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 81.8M |
| IPO Year | 1987 | N/A |
| Metric | FONR | NSPR |
|---|---|---|
| Price | $14.45 | $1.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 30.3K | ★ 64.4K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $105,434,318.00 | $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | 3.36 | ★ 14.04 |
| 52 Week Low | $12.00 | $1.59 |
| 52 Week High | $17.62 | $3.80 |
| Indicator | FONR | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 47.94 |
| Support Level | $14.35 | $1.89 |
| Resistance Level | $15.19 | $2.17 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 39.04 | 50.00 |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.